Most patients had ductal carcinoma (75%), intermediate grade (62%), stage IA (60%), HR + (89%; 88% ER + , 80% PGR +) and HER2- (88%) tumors. This evidence concerns the gene ERBB2 and breast ductal adenocarcinoma.